Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Burkitt Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Lymphoma, B-Cell 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

Carboplatin 27pembrolizumab 26Cisplatin 24Paclitaxel 21Nivolumab 19Gemcitabine 16Pemetrexed 14Rituximab 14Ipilimumab 12Cyclophosphamide 11Dexamethasone 11Fluorouracil 10Capecitabine 9Docetaxel 9durvalumab 9trastuzumab deruxtecan 9Lenalidomide 8Oxaliplatin 8atezolizumab 8Doxorubicin 7daratumumab 7osimertinib 7Bortezomib 6Cytarabine 6Leucovorin 6Trastuzumab 6olaparib 6venetoclax 6130-nm albumin-bound paclitaxel 5Ado-Trastuzumab Emtansine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has announcements × Methotrexate × 1 year × Clear all
NCT02003222 2026-05-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01516580 2026-02-09

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Completed
482 enrolled 1 FDA
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Takeda

Phase 3 Active not recruiting
245 enrolled 15 charts 1 FDA
LymphoidOther hematologic neoplasm

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡